Figure 5. CircABCB10 contributes to LSCC progression by miR-588/CXCR4 axis. (A–D) The AMC-HN-8 and Hep-2 cells were treated control shRNA, circABCB10 shRNA, or co-treated with circABCB10 shRNA and miR-588 inhibitor or pcDNA-CXCR4. (A and B) The cell viability was analyzed by MTT assays in the cells. (C and D) The cell apoptosis was tested by flow cytometry analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: **P < 0.01.